Recombinant gamma interferon and in vivo induction of HLA-DR antigens.
Recombinant human IFN-gamma, used for treatment of melanoma and renal carcinoma, was found to induce HLA-DR expression on human keratinocytes in vivo. HLA-DR antigens bound to keratinocytes of the basal and suprabasal layers of the epidermis were observed after intramuscular or intravenous injections of 0.5 mg/kg body weight IFN-gamma, 3 times a week. Keratinocyte-bound HLA-DR antigens were first observed at the beginning of the third or fourth week of treatment, but HLA-DQ and HLA-DP antigens were never detected on keratinocytes. The intracytoplasmic constant (gamma) chain of the class II molecules was also not detectable within the keratinocytes. Patients who received IFN-alpha 2 therapy, did not exhibit keratinocyte-bound HLA-DR antigens.
Volc-Platzer
B
B
Department of Dermatology I, University of Vienna, Austria.
Steiner
A
A
Radaszkiewicz
T
T
Wolff
K
K
D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D007633:Keratins; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D011994:Recombinant Proteins; D012867:Skin / Q000276:immunology*
D006684:HLA-DR Antigens; D011994:Recombinant Proteins; D007633:Keratins; D007371:Interferon-gamma